The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis
The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
Nonalcoholic steatohepatitis (NASH) and alcoholic hepatitis (ASH) are advanced forms of fatty liver diseases that are associated with a high morbidity and mortality worldwide. Patients with ASH or NASH are more susceptible to the progression of fibrosis and cirrhosis up to the development of hepatocellular carcinoma. Currently, there are limited medical therapies available. Accompanied by the asymptomatic disease progression, the demand for liver transplants is high. This review provides an overview about the growing evidence for a central role of NLR family pyrin domain containing 3 (NLRP3) inflammasome, a multiprotein complex that acts as a central driver of inflammation via activation of caspase 1, maturation and release of pro-inflammatory cytokines including interleukin-1β, and trigger of inflammatory pyroptotic cell death in both NASH and ASH. We also discuss potential therapeutic approaches targeting NLRP3 inflammasome and related upstream and downstream pathways to develop prognostic biomarkers and medical treatments for both liver diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nonetheless, rodent models emphasise the importance of NLRP3 activation for inflammatory macrophage as well as fibrogenic stellate cell responses.64”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [64]
In the citing paper
“In NAFLD and NASH, the NLR family pyrin domain containing 3 (NLRP3) inflammasome has been identified as a central driver of inflammation – via activation of caspase 1 and the release of inflammatory cytokines (e.g., IL-1β) – and as an inducer of inflammatory (“pyroptotic”) cell death.64”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [64]
Citations
Cites
Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death
Shi, J., Zhao, Y., Wang, K., Shi, X., Wang, Y., Huang, H., Zhuang, Y., Cai, T., Wang, F., & Shao, F. (2015) · Nature · doi:10.1038/nature15514 · Cited by 6,659
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling
Kayagaki, N., Stowe, I. B., Lee, B. L., O’Rourke, K., Anderson, K., Warming, S., Cuellar, T., Haley, B., Roose-Girma, M., Phung, Q. T., et al. (2015) · Nature · doi:10.1038/nature15541 · Cited by 3,686
Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Liu, X., Zhang, Z., Ruan, J., Pan, Y., Magupalli, V. G., Wu, H., & Lieberman, J. (2016) · Nature · doi:10.1038/nature18629 · Cited by 3,202
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
Estes, C., Anstee, Q. M., Arias-Loste, M. T., Bantel, H., Bellentani, S., Caballeria, J., Colombo, M., Craxi, A., Crespo, J., Day, C. P., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.036 · Cited by 1,980
Self-citationDulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., Wai‐Sun Wong, V., Yilmaz, Y., George, J., Fan, J., et al. (2019) · Hepatology · doi:10.1002/hep.30251 · Cited by 1,858
Self-citationZhu, L., Baker, S. S., Gill, C., Liu, W., Alkhouri, R., Baker, R. D., & Gill, S. R. (2013) · Hepatology · doi:10.1002/hep.26093 · Cited by 1,708
Loomba, R., & Sanyal, A. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.171 · Cited by 1,641
Boursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo‐Perez, F., Guy, C. D., Seed, P. C., Rawls, J. F., David, L. A., et al. (2016) · Hepatology · doi:10.1002/hep.28356 · Cited by 1,483
NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
Mridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., Haczeyni, F., Teoh, N. C.-H., Savard, C., Ioannou, G. N., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.022 · Cited by 1,110
Self-citationO'Shea, R. S., Dasarathy, S., & McCullough, A. J. (2010) · Hepatology · doi:10.1002/hep.23258 · Cited by 1,077
Leclercq, S., Matamoros, S., Cani, P. D., Neyrinck, A. M., Jamar, F., Stärkel, P., Windey, K., Tremaroli, V., Bäckhed, F., Verbeke, K., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415174111 · Cited by 972
Brun, P., Castagliuolo, I., Leo, V. D., Buda, A., Pinzani, M., Palù, G., & Martines, D. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00024.2006 · Cited by 864
Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease
Duan, Y., Llorente, C., Lang, S., Brandl, K., Chu, H., Jiang, L., White, R. C., Clarke, T. H., Nguyen, K., Torralba, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1742-x · Cited by 844
Colonic microbiome is altered in alcoholism
Mutlu, E. A., Gillevet, P. M., Rangwala, H., Sikaroodi, M., Naqvi, A., Engen, P. A., Kwasny, M., Lau, C. K., & Keshavarzian, A. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00380.2011 · Cited by 775
Prednisolone or Pentoxifylline for Alcoholic Hepatitis
Thursz, M. R., Richardson, P., Allison, M., Austin, A., Bowers, M., Day, C. P., Downs, N., Gleeson, D., MacGilchrist, A., Grant, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412278 · Cited by 769
Gut–Liver Axis in Alcoholic Liver Disease
Szabo, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.042 · Cited by 754
IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice
Petrasek, J., Bala, S., Csak, T., Lippai, D., Kodys, K., Menashy, V., Barrieau, M., Min, S.-Y., Kurt-Jones, E. A., & Szabo, G. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60777 · Cited by 735
Upregulated NLRP3 Inflammasome Activation in Patients With Type 2 Diabetes
Lee, H.-M., Kim, J.-J., Kim, H. J., Shong, M., Ku, B. J., & Jo, E.-K. (2013) · Diabetes · doi:10.2337/db12-0420 · Cited by 734
Rivera, C. A., Adegboyega, P., van Rooijen, N., Tagalicud, A., Allman, M., & Wallace, M. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.04.019 · Cited by 693
Csak, T., Ganz, M., Pespisa, J., Kodys, K., Dolganiuc, A., & Szabo, G. (2011) · Hepatology · doi:10.1002/hep.24341 · Cited by 645
Alcohol and hepatocellular carcinoma
Morgan, T. R., Mandayam, S., & Jamal, M. M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.020 · Cited by 625
Rathkey, J. K., Zhao, J., Liu, Z., Chen, Y., Yang, J., Kondolf, H. C., Benson, B. L., Chirieleison, S. M., Huang, A. Y., Dubyak, G. R., et al. (2018) · Science Immunology · doi:10.1126/sciimmunol.aat2738 · Cited by 612
Anti-inflammatory Compounds Parthenolide and Bay 11-7082 Are Direct Inhibitors of the Inflammasome
Juliana, C., Fernandes-Alnemri, T., Wu, J., Datta, P., Solorzano, L., Yu, J.-W., Meng, R., Quong, A. A., Latz, E., Scott, C. P., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.082305 · Cited by 610
Innate Immunity and Inflammation in NAFLD/NASH
Arrese, M., Cabrera, D., Kalergis, A. M., & Feldstein, A. E. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4049-x · Cited by 492
Self-citationNLRP3 inflammasome activation is required for fibrosis development in NAFLD
Wree, A., McGeough, M. D., Peña, C. A., Schlattjan, M., Li, H., Inzaugarat, M. E., Messer, K., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1170-1 · Cited by 486
Self-citationNaveau, S., Chollet-Martin, S., Dharancy, S., Mathurin, P., Jouet, P., Piquet, M.-A., Davion, T., Oberti, F., Broët, P., & Emilie, D. (2004) · Hepatology · doi:10.1002/hep.20206 · Cited by 446
Xu, B., Jiang, M., Chu, Y., Wang, W., Chen, D., Li, X., Zhang, Z., Zhang, D., Fan, D., Nie, Y., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.040 · Cited by 426
Inflammatory pathways in alcoholic steatohepatitis
Gao, B., Ahmad, M. F., Nagy, L. E., & Tsukamoto, H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.023 · Cited by 392
Machado, M. V., Michelotti, G. A., Xie, G., de Almeida, T. P., Boursier, J., Bohnic, B., Guy, C. D., & Diehl, A. M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0127991 · Cited by 380
Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial
Zein, C. O., Yerian, L. M., Gogate, P., Lopez, R., Kirwan, J. P., Feldstein, A. E., & McCullough, A. J. (2011) · Hepatology · doi:10.1002/hep.24544 · Cited by 356
Self-citationDifferential Expression of NLRP3 among Hematopoietic Cells
Guarda, G., Zenger, M., Yazdi, A. S., Schroder, K., Ferrero, I., Menu, P., Tardivel, A., Mattmann, C., & Tschopp, J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002720 · Cited by 350
Pathological Features of Fatty Liver Disease
Yeh, M. M., & Brunt, E. M. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.056 · Cited by 346
Wong, V. W.-S., Tse, C.-H., Lam, T. T.-Y., Wong, G. L.-H., Chim, A. M.-L., Chu, W. C.-W., Yeung, D. K.-W., Law, P. T.-W., Kwan, H.-S., Yu, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062885 · Cited by 342
Wannamaker, W., Davies, R., Namchuk, M., Pollard, J., Ford, P., Ku, G., Decker, C., Charifson, P., Weber, P., Germann, U. A., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.111344 · Cited by 315
Cholankeril, G., & Ahmed, A. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.11.045 · Cited by 274
Neutrophils contribute to spontaneous resolution of liver inflammation and fibrosis via microRNA-223
Calvente, C. J., Tameda, M., Johnson, C. D., del Pilar, H., Lin, Y. C., Adronikou, N., De Mollerat Du Jeu, X., Llorente, C., Boyer, J., & Feldstein, A. E. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122258 · Cited by 268
Self-citationHeo, M. J., Kim, T. H., You, J. S., Blaya, D., Sancho-Bru, P., & Kim, S. G. (2019) · Gut · doi:10.1136/gutjnl-2017-315123 · Cited by 255
Microbiome as a therapeutic target in alcohol-related liver disease
Sarin, S. K., Pande, A., & Schnabl, B. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.019 · Cited by 253
Cohen, S. B., Proudman, S., Kivitz, A. J., Burch, F. X., Donohue, J. P., Burstein, D., Sun, Y.-N., Banfield, C., Vincent, M. S., Ni, L., et al. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3430 · Cited by 246
Booshehri, L. M., & Hoffman, H. M. (2019) · Journal of Clinical Immunology · doi:10.1007/s10875-019-00638-z · Cited by 239
Lang, S., Duan, Y., Liu, J., Torralba, M. G., Kuelbs, C., Ventura‐Cots, M., Abraldes, J. G., Bosques‐Padilla, F., Verna, E. C., Brown, R. S., et al. (2020) · Hepatology · doi:10.1002/hep.30832 · Cited by 236
Pyroptosis by caspase11/4‐gasdermin‐D pathway in alcoholic hepatitis in mice and patients
Khanova, E., Wu, R., Wang, W., Yan, R., Chen, Y., French, S. W., Llorente, C., Pan, S. Q., Yang, Q., Li, Y., et al. (2018) · Hepatology · doi:10.1002/hep.29645 · Cited by 228
Honda, H., Nagai, Y., Matsunaga, T., Okamoto, N., Watanabe, Y., Tsuneyama, K., Hayashi, H., Fujii, I., Ikutani, M., Hirai, Y., et al. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a0114-005rr · Cited by 211
Mechanisms of disease: inflammasome activation and the development of type 2 diabetes
Grant, R. W., & Dixit, V. D. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00050 · Cited by 203
Stack, J. H., Beaumont, K., Larsen, P. D., Straley, K. S., Henkel, G. W., Randle, J. C. R., & Hoffman, H. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2630 · Cited by 190
Caspase-1 as a Central Regulator of High Fat Diet-Induced Non-Alcoholic Steatohepatitis
Dixon, L. J., Flask, C. A., Papouchado, B. G., Feldstein, A. E., & Nagy, L. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056100 · Cited by 188
Self-citationRecent insights into the molecular mechanisms of the NLRP3 inflammasome activation
Próchnicki, T., Mangan, M. S., & Latz, E. (2016) · F1000Research · doi:10.12688/f1000research.8614.1 · Cited by 176
Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis
Dixon, L. J., Berk, M., Thapaliya, S., Papouchado, B. G., & Feldstein, A. E. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.45 · Cited by 158
Self-citationPetrasek, J., Iracheta-Vellve, A., Saha, B., Satishchandran, A., Kodys, K., Fitzgerald, K. A., Kurt-Jones, E. A., & Szabo, G. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ab1214-590r · Cited by 152
Hoyt, L. R., Randall, M. J., Ather, J. L., DePuccio, D. P., Landry, C. C., Qian, X., Janssen-Heininger, Y. M. W., van der Vliet, A., Dixon, A. E., Amiel, E., et al. (2017) · Redox Biology · doi:10.1016/j.redox.2017.04.020 · Cited by 143
Alcoholic liver disease: A current molecular and clinical perspective
Ohashi, K., Pimienta, M., & Seki, E. (2018) · Liver Research · doi:10.1016/j.livres.2018.11.002 · Cited by 142
Iracheta-Vellve, A., Petrasek, J., Satishchandran, A., Gyongyosi, B., Saha, B., Kodys, K., Fitzgerald, K. A., Kurt-Jones, E. A., & Szabo, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.013 · Cited by 136
Goossens, G. H., Blaak, E. E., Theunissen, R. O. M. F. I. H., Duijvestijn, A. M., Clément, K., Tervaert, J.-W. C., & Thewissen, M. M. (2012) · Molecular Immunology · doi:10.1016/j.molimm.2012.01.005 · Cited by 121
Pihlajamäki, J., Kuulasmaa, T., Kamińska, D., Simonen, M., Kärjä, V. J., Grönlund, S., Käkelä, P., Pääkkönen, M. E., Kainulainen, S., Punnonen, K. R. A., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.005 · Cited by 116
MicroRNA 223 3p Negatively Regulates the NLRP3 Inflammasome in Acute and Chronic Liver Injury
Jimenez Calvente, C., Del Pilar, H., Tameda, M., Johnson, C. D., & Feldstein, A. E. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.013 · Cited by 110
Self-citationPerspectives on Treatment for Nonalcoholic Steatohepatitis
Lassailly, G., Caiazzo, R. J., Pattou, F. N., & Mathurin, P. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.004 · Cited by 94
Cabrera, D., Wree, A., Povero, D., Solís, N., Hernandez, A., Pizarro, M., Moshage, H., Torres, J., Feldstein, A. E., Cabello-Verrugio, C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-03675-z · Cited by 86
Self-citationAlcohol withdrawal alleviates adipose tissue inflammation in patients with alcoholic liver disease
Voican, C. S., Njiké‐Nakseu, M., Boujedidi, H., Barri‐Ova, N., Bouchet‐Delbos, L., Agostini, H., Maitre, S., Prévot, S., Cassard‐Doulcier, A., Naveau, S., et al. (2015) · Liver International · doi:10.1111/liv.12575 · Cited by 79
The role of the inflammasome in nonmyeloid cells
Yazdi, A. S., Drexler, S. K., & Tschopp, J. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9437-y · Cited by 76
He, K., Zhu, X., Liu, Y., Miao, C., Wang, T., Li, P., Zhao, L., Chen, Y., Gong, J., Cai, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17489 · Cited by 73
Nurmi, K., Virkanen, J., Rajamäki, K., Niemi, K., Kovanen, P. T., & Eklund, K. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078537 · Cited by 70
Morrison, M. C., Mulder, P., Salic, K., Verheij, J., Liang, W., van Duyvenvoorde, W., Menke, A., Kooistra, T., Kleemann, R., & Wielinga, P. Y. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.74 · Cited by 63
Hoyt, L. R., Ather, J. L., Randall, M. J., DePuccio, D. P., Landry, C. C., Wewers, M. D., Gavrilin, M. A., & Poynter, M. E. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600406 · Cited by 51
The therapeutic landscape of non‐alcoholic steatohepatitis
Perazzo, H., & Dufour, J. (2017) · Liver International · doi:10.1111/liv.13270 · Cited by 49
The inflammasome in alcoholic hepatitis: Its relationship with Mallory–Denk body formation
Peng, Y., French, B. A., Tillman, B., Morgan, T. R., & French, S. W. (2014) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2014.08.006 · Cited by 44
Thomas, M. G., Bayliss, C., Bond, S. J., Dowling, F., Galea, J. P., Jairath, V., Lamb, C. A., Probert, C. S., Timperley-Preece, E., Watson, A. J. M., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-023765 · Cited by 43
Blasetti Fantauzzi, C., Menini, S., Iacobini, C., Rossi, C., Santini, E., Solini, A., & Pugliese, G. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/8962458 · Cited by 36
Nakanishi, K., Kaji, K., Kitade, M., Kubo, T., Furukawa, M., Saikawa, S., Shimozato, N., Sato, S., Seki, K., Kawaratani, H., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112724 · Cited by 34
Ethanol upregulates the P2X7 purinergic receptor in human macrophages
Daré, B. L., Victoni, T., Bodin, A., Vlach, M., Vène, É., Loyer, P., Lagente, V., & Gicquel, T. (2018) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12433 · Cited by 26
Giuffrè, M., Macor, D., Masutti, F., Abazia, C., Tinè, F., Patti, R., Buonocore, M. R., Colombo, A., Visintin, A., Campigotto, M., et al. (2018) · Hepatology · doi:10.1002/hep.30353 · Cited by 21
Cited by
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
“Inhibition of TLR4 or inflammasome activation demonstrated preclinical efficacy in mouse models but is currently not in late-stage development for the treatment of liver fibrosis 21,222 .”
Self-citationWen, Y., Lambrecht, J., Ju, C., & Tacke, F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00558-8 · Cited by 695
“The role of macrophage inflammasome activation in chronic liver diseases, such as ALD and NASH, has also been reported.(100) IL-1β, which is released as a result of inflammasome activation in KCs, plays a critical role in mediating alcohol-induced steatosis, inflammation, and liver injury.”
BackgroundSelf-citationMolecular Mechanisms That Link Oxidative Stress, Inflammation, and Fibrosis in the Liver
Ramos-Tovar, E., & Muriel, P. (2020) · Antioxidants · doi:10.3390/antiox9121279 · Cited by 340
Taru, V., Szabo, G., Mehal, W., & Reiberger, T. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.016 · Cited by 344
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Self-citation
Metadata
- Authors
- Knorr, J., Wree, A., Tacke, F., & Feldstein, A. E.
- Affiliations
- Stiftung Charité (DE)
- University of California San Diego (US)
- Corresponding author
- Feldstein, Ariel E.
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 2020-06-11
- Volume
- 40
- Issue
- 03
- Pages
- 298-306
- ISSN
- 0272-8087 (ISSN-L)
- 1098-8971
- OpenAlex
- W3035320104
- Semantic Scholar
- 037be5799886122d7579dfbba835734266590c6a
- Cited by
- 99
- References
- 77
- Citations by year
- 2026: 10 · 2025: 6 · 2024: 20 · 2023: 22 · 2022: 27 · 2021: 9 · 2020: 5
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Seminars in Liver Disease (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIH (R01 DK113592, U01 AA024206)
- German Research Foundation (WR173/3–1, SFB/TRR57)
- German Cancer Aid (70113000)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- NLRP3 inflammasome, nonalcoholic steatohepatitis, alcoholic hepatitis, hepatic steatosis, caspase-1, IL-1β, pyroptosis, liver inflammation, liver fibrosis, liver cirrhosis, hepatocellular carcinoma, therapeutic target, prognostic factors
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Fatty Liver, Alcoholic, Female, Humans, Male, Disease Progression, Mice, Inflammasomes, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.